MX9709447A - Nueva muteina cd4ol. - Google Patents

Nueva muteina cd4ol.

Info

Publication number
MX9709447A
MX9709447A MX9709447A MX9709447A MX9709447A MX 9709447 A MX9709447 A MX 9709447A MX 9709447 A MX9709447 A MX 9709447A MX 9709447 A MX9709447 A MX 9709447A MX 9709447 A MX9709447 A MX 9709447A
Authority
MX
Mexico
Prior art keywords
mutein
novel
cd40l mutein
novel cd40l
cd40l
Prior art date
Application number
MX9709447A
Other languages
English (en)
Other versions
MXPA97009447A (es
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Marylou G Gibson
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,733 external-priority patent/US5981724A/en
Priority claimed from US08/484,624 external-priority patent/US5962406A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA97009447A publication Critical patent/MXPA97009447A/es
Publication of MX9709447A publication Critical patent/MX9709447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)

Abstract

Se describe un polipéptido que es una muteína de CD4OL, y secuencias de DNA, vectores y células huésped transformadas utiles.
MX9709447A 1995-06-07 1996-06-06 Nueva muteina cd4ol. MX9709447A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/477,733 US5981724A (en) 1991-10-25 1995-06-07 DNA encoding CD40 ligand, a cytokine that binds CD40
US08484624 1995-06-07
US08477733 1995-06-07
US08/484,624 US5962406A (en) 1991-10-25 1995-06-07 Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
PCT/US1996/009632 WO1996040918A2 (en) 1995-06-07 1996-06-06 Novel cd40l mutein

Publications (2)

Publication Number Publication Date
MXPA97009447A MXPA97009447A (es) 1998-02-01
MX9709447A true MX9709447A (es) 1998-02-28

Family

ID=27045653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9709447A MX9709447A (es) 1995-06-07 1996-06-06 Nueva muteina cd4ol.

Country Status (15)

Country Link
EP (1) EP0832229B1 (es)
JP (1) JP3279573B2 (es)
KR (1) KR100453314B1 (es)
AT (1) ATE257858T1 (es)
AU (1) AU693713B2 (es)
CA (1) CA2222914C (es)
DE (1) DE69631331T2 (es)
DK (1) DK0832229T3 (es)
ES (1) ES2214541T3 (es)
IL (1) IL122174A (es)
MX (1) MX9709447A (es)
NO (1) NO317735B1 (es)
NZ (1) NZ311335A (es)
PT (1) PT832229E (es)
WO (1) WO1996040918A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2001090382A2 (fr) * 2000-05-26 2001-11-29 Mochida Pharm Co Ltd Proteines de fusion agissant en tant que fas-ligand
EP3187592B1 (en) 2001-09-20 2018-12-12 Immunex Corporation Selection of cells expressing heteromeric polypeptides
AU2004213797B2 (en) 2003-02-14 2009-09-17 Biogen Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
WO2005035570A2 (en) * 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
RU2007118954A (ru) 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
SG174804A1 (es) 2006-09-13 2011-10-28 Abbott Lab
MY188753A (en) 2006-09-18 2021-12-29 Univ Arkansas Compositions and methods of enhancing immune responses
US8222016B2 (en) 2007-06-29 2012-07-17 Daiichi Sankyo Company, Limited Recombinant C-terminal α-amidating enzyme derivative
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
NZ585777A (en) 2007-11-01 2012-09-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
CN101970655B (zh) 2008-01-15 2014-03-05 Abbvie公司 改良哺乳动物表达载体及其用途
US8765415B2 (en) 2009-11-17 2014-07-01 Medarex, L.L.C. Methods for enhanced protein production
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
ES2758759T3 (es) 2013-02-14 2020-05-06 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a eimeria o limitar la infección por eimeria
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
WO2017024146A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
EP3452069A4 (en) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
MA44976A (fr) 2016-05-11 2019-03-20 Amgen Inc Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase
EP3455263A4 (en) * 2016-05-13 2020-01-01 MedImmune, LLC CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0822199T3 (da) * 1991-10-25 2004-12-27 Amgen Inc N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP3589665B2 (ja) * 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法

Also Published As

Publication number Publication date
IL122174A0 (en) 1998-04-05
NO317735B1 (no) 2004-12-13
DK0832229T3 (da) 2004-05-03
PT832229E (pt) 2004-06-30
CA2222914A1 (en) 1996-12-19
EP0832229B1 (en) 2004-01-14
ATE257858T1 (de) 2004-01-15
KR19990022141A (ko) 1999-03-25
NZ311335A (en) 1998-05-27
NO975437D0 (no) 1997-11-26
KR100453314B1 (ko) 2004-12-17
WO1996040918A2 (en) 1996-12-19
NO975437L (no) 1998-02-06
WO1996040918A3 (en) 1997-01-23
EP0832229A2 (en) 1998-04-01
ES2214541T3 (es) 2004-09-16
AU693713B2 (en) 1998-07-02
AU6263896A (en) 1996-12-30
DE69631331D1 (de) 2004-02-19
JPH11504819A (ja) 1999-05-11
DE69631331T2 (de) 2004-11-18
JP3279573B2 (ja) 2002-04-30
CA2222914C (en) 2002-04-02
IL122174A (en) 2004-07-25

Similar Documents

Publication Publication Date Title
IL122174A0 (en) Novel CD40L mutein
DE69425906D1 (en) Interleukin-15
AU5099293A (en) CD27 ligand
CA2121798A1 (en) Novel cytokine
HU9503618D0 (en) Recombinant stratum corneum chymotryptic enzyme (scce)
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
EP0731806A4 (en) SPECIFIC FUSION NUCLEIC ACIDS AND PROTEINS IN HUMAN T (2; 5) LYMPHOMAS, METHOD FOR THEIR DETECTION AND THEIR USE
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
CA2126356A1 (fr) Serum-albumine humaine, preparation et utilisation
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
AU3502089A (en) Bacillus thuringiensis transformation
AU1435695A (en) Recombinant human thymopoietin proteins and uses therefor
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
GB9203821D0 (en) Improvements in or relating to malaria vaccine
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
CA2217633A1 (en) Genes encoding lymphocyte interferon regulatory factor (lsirf) polypeptides
AU3928193A (en) Plasmilar gene, peptide and methods of use
AU6981794A (en) Protein which catalyses peptide refolding and uses thereof
AU9272598A (en) Bovine herpesvirus 2 (bhv-2) based vector and its uses
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same
AU6371894A (en) A nucleotide sequence encoding a chromosomal protein, associated chromosomal proteins and their uses
AU7718294A (en) Mammalian stromal cell proteins and dna sequences coding therefor

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees